The DYNAMIC-III trial enrolled over 1,000 participants diagnosed with stage 3 colon cancer from Australia, New Zealand, and Canada. All patients underwent surgical resection aimed at removing the primary tumor. Approximately six weeks post-surgery, blood samples were collected for analysis of ctDNA, cancer-derived genetic fragments shed into the bloodstream through tumor cell apoptosis or necrosis. Detection of ctDNA after surgery acts as a highly sensitive biomarker for residual microscopic disease lurking beyond the reach of conventional imaging techniques.

Patients were stratified into two categories based on their ctDNA status: “low-risk” if no ctDNA was detectable, and “high-risk” if ctDNA fragments were present in circulation. This molecular categorization then guided randomized treatment allocations, comparing ctDNA-directed adjuvant chemotherapy regimens against standard chemotherapy protocols. The fundamental goal was to determine whether ctDNA testing could safely reduce overtreatment while maintaining cancer-free survival outcomes, representing a leap toward personalized medicine in colorectal oncology.

Professor Jeanne Tie from WEHI, a leading oncologist and the trial’s principal investigator, emphasizes that ctDNA-guided therapy embodies the future of precision oncology in this setting. While current guidelines advocate uniform administration of chemotherapy for all stage 3 colon cancer patients, often resulting in unnecessary exposure to cytotoxic drugs and associated toxicities, ctDNA assays can tailor treatment intensity based on molecular evidence of minimal residual disease (MRD). This nuanced approach ensures patients without detectable tumor DNA avoid the harsh side effects of chemotherapy like oxaliplatin-induced neuropathy without compromising survival chances.

The clinical data underscore the promise of this strategy. Patients categorized as ctDNA-negative post-surgery experienced remarkably favorable outcomes, with an impressive 87 percent remaining disease-free three years later. This suggests that a less aggressive chemo regimen or even omission of chemotherapy can be safe and effective in patients demonstrating molecular remission. Such precision spares patients from the physical and emotional burdens intrinsic to chemotherapy, substantially enhancing quality of life while preserving clinical efficacy.

Conversely, individuals with persistent ctDNA positivity faced a substantially elevated risk of recurrence. The study showed that only about half of these patients remained cancer-free at the three-year mark. Moreover, analysis revealed a dose-response relationship, where increasing ctDNA levels correlated with higher chances of tumor relapse. Importantly, intensification of chemotherapy in this subgroup did not improve outcomes, illuminating an urgent need for novel therapeutic strategies capable of targeting the biological pathways driving resistant or residual disease.

These findings were made possible through a seamless collaboration among several prominent organizations, including the Canadian Cancer Trials Group (CCTG), the Australasian Gastrointestinal Trials Group (AGITG), and the Peter MacCallum Cancer Centre. This multinational, multidisciplinary effort attests to the robustness and generalizability of the results, providing a strong impetus to integrate ctDNA testing into clinical oncology workflows globally.

Dr Jonathan Loree, Canadian senior investigator and DYNAMIC-III trial chair, highlights the study as the most compelling prospective evidence of ctDNA’s prognostic and predictive utility in resected stage 3 colon cancer to date. The trial’s rigorously designed randomized methodology addresses prior limitations in ctDNA research, establishing clinical validity that could fast-track incorporation into treatment guidelines. Dr Loree further stresses that these insights could also pave the way for refinements in other tumor types where MRD biomarkers hold promise.

Colorectal cancer remains a leading cause of cancer morbidity and mortality worldwide, with over 15,000 new diagnoses anticipated in Australia alone in 2024. This novel ctDNA-based liquid biopsy represents a paradigm shift, moving beyond traditional staging and histopathological factors to molecularly informed therapeutic decisions. Such advancements demonstrate how liquid biopsies, an emerging frontier in oncology, can revolutionize early detection of relapse, optimize adjuvant chemotherapy use, and ultimately improve patient survival.

The implications extend beyond clinical outcomes, promising a substantial reduction in healthcare costs and burden on patients’ lives by minimizing unnecessary treatments. By personalizing therapeutic interventions based on real-time molecular surveillance, DYNAMIC-III exemplifies how precision medicine is reshaping cancer care in the 21st century, reaffirming the critical role of translational research and international collaboration in advancing oncology.

In summary, the DYNAMIC-III trial decisively proves that ctDNA can serve as a sensitive, non-invasive biomarker to guide adjuvant chemotherapy in stage 3 colon cancer. This approach spares low-risk patients from unwarranted chemotherapy toxicity while identifying those at genuine high risk who require closer monitoring and potentially novel therapeutic approaches. As the oncology community embraces this innovation, patients stand to benefit from safer, more efficacious, and truly individualized treatment strategies that align with the molecular underpinnings of their disease.

Subject of Research: People

Article Title: Circulating Tumor DNA-Guided Adjuvant Therapy in Locally Advanced Colon Cancer: the Randomized Phase 2/3 DYNAMIC-III Trial

Web References:
10.1038/s41591-025-04030-w

Image Credits: WEHI

Keywords: Colon cancer, Cancer, Circulating tumor DNA, ctDNA, Adjuvant chemotherapy, Precision medicine, Minimal residual disease, Liquid biopsy

Stage 3 colon cancer is characterized by tumor invasion beyond the mucosal lining into regional lymph nodes. Historically, management has relied on adjuvant chemotherapy with fluoropyrimidine-based regimens combined with oxaliplatin, a protocol that, while effective, frequently exposes patients to severe toxicities, including persistent neuropathy related to oxaliplatin. The DYNAMIC-III trial innovatively leveraged postoperative ctDNA status to tailor therapeutic intensity—escalating chemotherapy for ctDNA-positive patients who harbor residual microscopic disease and de-escalating treatment for ctDNA-negative patients who presumably have minimal relapse risk.

The trial enrolled 1,002 patients within five to six weeks of surgery, dividing them between ctDNA-guided therapy and conventional treatment arms. Those testing positive for ctDNA received intensified treatment, with approximately half administered a triplet chemotherapy regimen called FOLFOXIRI, incorporating folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan, designed to aggressively combat residual disease. Conversely, ctDNA-negative patients underwent reduced chemotherapy courses, primarily entailing lower doses or shorter durations of oxaliplatin-based doublets. This stratification was aimed at conserving patient quality of life by circumventing overtreatment without compromising oncological outcomes.

After a median follow-up of nearly four years, the ctDNA-negative cohort exhibited a remarkable 49% recurrence rate reduction compared to ctDNA-positive counterparts, underscoring ctDNA’s robust prognostic capacity. Importantly, ctDNA-guided de-escalation correlated with substantial declines in chemotherapy-associated morbidities, including a 54% reduction in oxaliplatin use, fewer hospital admissions, and diminished high-grade adverse events. Notably, three-year recurrence-free survival remained comparably high in the de-escalated group, suggesting that minimizing chemotherapy exposure did not significantly compromise disease control in low-risk patients.

However, escalation for ctDNA-positive patients did not yield proportional survival benefits when juxtaposed with standard care. Recurrence-free survival at two years was 51% in patients receiving intensified treatment versus 61% in those undergoing conventional therapy, suggesting innate chemoresistance or biological aggressiveness in these tumors. This gap signals an urgent need for innovative therapeutic avenues or adjunct modalities tailored to ctDNA-positive disease biology to enhance patient outcomes.

One of the most compelling revelations of the DYNAMIC-III study is the stark prognostic divide between patients with persistent ctDNA post-chemotherapy and those whose ctDNA clears. Persistent ctDNA correlated with a dismal three-year recurrence-free survival rate of 14%, contrasting sharply with 79% for patients demonstrating ctDNA clearance, indicating that ctDNA dynamics may become critical biomarkers for real-time treatment monitoring and risk-adapted clinical decision-making.

An intriguing aspect of the data involved recurrence patterns among ctDNA-negative patients, wherein relapse predominantly occurred at anatomical sites such as the lungs and peritoneum—regions that seemingly release less ctDNA into circulation—highlighting inherent limitations in ctDNA detection sensitivity. These findings accentuate that while ctDNA is transformative, it may require integration with complementary imaging or molecular modalities to comprehensively gauge minimal residual disease burdens.

The paradigm-shifting implications of the DYNAMIC-III trial echo the pioneering conceptual groundwork laid by Bert Vogelstein and colleagues. Their seminal discoveries elucidated the genetic mutational sequences driving colon carcinogenesis, laid the foundation for liquid biopsy technologies, and opened avenues for non-invasive tumor surveillance through ctDNA profiling. These advances now converge to inform clinical practice, promising to alleviate patient burden by obviating unnecessary chemotherapy and focusing intensified treatment where most needed.

Contextually, this study builds upon earlier evidence endorsing ctDNA’s utility in Stage 2 colon cancer, thereby bolstering the momentum toward widespread adoption of ctDNA-guided personalized medicine frameworks. By integrating molecular biomarkers into therapeutic algorithms, clinicians inch closer to an era where interventions are precisely calibrated to tumor biology and individual patient risk, a transformative shift from the one-size-fits-all approaches of yesteryear.

Moving forward, the integration of ctDNA assays across diverse tumor types, alongside ongoing refinements in assay sensitivity and specificity, could rapidly expand the scope of personalized oncology. However, challenges remain, particularly in defining optimal treatment intensification strategies for ctDNA-positive patients and enhancing ctDNA detection in sanctuary sites. Collaborative efforts involving molecular scientists, oncologists, and clinical trialists will be pivotal in translating these promising findings into routine clinical protocols and improved patient survival.

In sum, the DYNAMIC-III trial elucidates a pioneering use of ctDNA as a actionable biomarker, enabling tailored adjuvant chemotherapy in Stage 3 colon cancer that optimizes therapeutic efficacy while reducing unnecessary toxicity. This advancement represents a milestone in precision cancer care, combining cutting-edge molecular diagnostics with patient-centric treatment paradigms to redefine standards of care and improve clinical outcomes.

Subject of Research: Circulating tumor DNA (ctDNA) as a biomarker to guide adjuvant chemotherapy in Stage 3 colon cancer.

Article Title: ctDNA-guided approach to adjuvant chemotherapy in stage 3 colon cancer.

News Publication Date: October 20 (year unspecified).

Web References:

• Johns Hopkins Kimmel Cancer Center: https://www.hopkinsmedicine.org/kimmel_cancer_center/
• European Society for Medical Oncology Congress 2025: https://www.esmo.org/meeting-calendar/esmo-congress-2025

References: Published in Nature Medicine on October 20.

Image Credits: Modified from Jeanne Tie, M.D.

Keywords: Cancer, Colon cancer, Circulating tumor DNA (ctDNA), Adjuvant chemotherapy, Precision medicine, Stage 3 colon cancer, Oncology, Chemotherapy de-escalation, Chemotherapy escalation, FOLFOXIRI, Minimal residual disease, Liquid biopsy